MAPT and myelodysplastic syndrome: To date, MDS has primarily been investigated using transgenic mice overexpressing the murine or human MECP2 transgene, such as the Tau-Mecp2 (Koerner et al., 2018; Luikenhuis et al., 2004), MECP2-TG (Collins et al., 2004), MECP2R11G-TG and MECP2R306-TG (Heckman et al., 2014), and hDup (Shao et al., 2021a) mouse models.